Screener
Arcutis Biotherapeutics, Inc. ARQT Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Arcutis Biotherapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
FAQ
- What is Arcutis Biotherapeutics, Inc.'s debt-to-equity?
- Arcutis Biotherapeutics, Inc. (ARQT) reported debt-to-equity of 0.5× in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s debt-to-equity changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s debt-to-equity decreased by 34.7% year-over-year, from 0.8× to 0.5×.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s debt-to-equity has grown at a 101.3% compound annual growth rate (CAGR), from 0× to 0.6×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Arcutis Biotherapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude